CCX-CKR^−/− mice develop EAE with enhanced kinetics and severity. Female CCX-CKR^−/− and wild-type C57BL/6 mice between 6-12 weeks of age were immunized for EAE and the clinical disease monitored daily. (A) Main graph: Clinical disease scores over a 28-day time course after immunization. Data are pooled from 3 separate experiments with 23 mice per group in total and are shown as the mean clinical disease score ± SEM (***P < .001 comparing CCX-CKR^−/− with wild-type using 2-way ANOVA). (Inset) Clinical disease scores between days 6 and 16 postimmunization (***P < .001 between CCX-CKR^−/− and wild-type mice using Bonferroni posttests on indicated days). (B) Day of onset and maximum scores of clinical disease symptoms from these experiments. Data shown are the mean day of onset ± SEM (***P < .001) and the mean maximum score ± SEM (***P < .001). (C) Mice were immunized for EAE and serum harvested from 5 or 6 mice per group per time point on days 0, 5, 12, and 21. Serum was then diluted 1/5 and analyzed for the presence of MOG_35-55-specific IgG by ELISA. Plotted is the mean optical density from each group ± SEM (**P < .01).